Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 14/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277599 | 0.94 | AGPAT2 (0.54) | AGPAT2HSP90AA1HSP90AB1DHFR | |
| SCHEMBL4289149 | 0.92 | AGPAT2 (0.53) | AGPAT2HSP90AA1HSP90AB1DHFR | |
| SCHEMBL4282695 | 0.90 | AGPAT2 (0.67) | AGPAT2HSP90AA1HSP90AB1DHFR | |
| SCHEMBL4291022 | 0.89 | AGPAT2 (0.52) | AGPAT2HSP90AA1HSP90AB1 | |
| SCHEMBL4277513 | 0.86 | AGPAT2 (0.49) | AGPAT2HSP90AA1HSP90AB1KDM4EALDH1A1 | |
| SCHEMBL3952206 | 0.83 | HSP90AA1 (0.68) | AGPAT2HSP90AA1HSP90AB1ALDH1A1MAPT | |
| SCHEMBL4280017 | 0.82 | AGPAT2 (0.50) | AGPAT2HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL13880319 | 0.81 | AGPAT2 (0.85) | AGPAT2 | |
| SCHEMBL4282091 | 0.81 | AGPAT2 (0.53) | AGPAT2HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL4279048 | 0.80 | HSP90AA1 (0.49) | AGPAT2HSP90AA1HSP90AB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | AGPAT2 100/4885HSP90AA1 4126/4885HSP90AB1 4236/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | AGPAT2 94/4885HSP90AA1 4006/4885HSP90AB1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.